dr zafar semaglutide Novo Nordisk India MD Vikrant Shrotriya discusses navigating the post-patent generic influx, the massive underpenetration of GLP-1 therapies, and how their once-weekly insulin, Awiqli, could double India's insulin market M. Zafar, MD, SC |
Pay in 4 interest-free payments of $5.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
65.jpg)



























